Sparks - Santhera Pharmaceuticals

Santhera Pharmaceuticals has delivered impressive H125 results, with total revenue surging 70% to CHF24m, driven by accelerating global AGAMREE sales. The Swiss specialty pharma company secured CHF20m in additional growth capital to meet increasing demand across key markets.

What’s going on here?
Santhera’s product sales jumped 76% to CHF11.6m, led by strong performance in Germany and Austria, plus first contributions from the UK following the Q2 launch. Global AGAMREE sales exceeded $100m on a four-quarter basis, triggering a $25m milestone payment that contributed to an operating loss of CHF35.4m. US partner Catalyst delivered strong H1 sales of $49.4m and is on track to achieve FY25 guidance of $100–110m, which would trigger an additional $12.5m milestone.

What does this mean?
The results demonstrate AGAMREE’s rapid market penetration as a new standard of care for Duchenne muscular dystrophy (DMD). In Germany, approximately 40% of steroid-using DMD patients now receive AGAMREE, while Austria has become the first country where over half of eligible patients are treated with the drug. Chinese partner Sperogenix commenced commercial roll-out in September, with over 250 patients treated to date. Pricing and reimbursement discussions are advancing across Spain, Italy and the Nordic regions, with launches expected from Q425 into Q126.

Why should I care?
The CHF20m financing comprises $13m from a royalty monetisation with R-Bridge and CHF10m from an extended convertible bond with Highbridge, bringing total pro forma cash to c CHF38m. With full-year 2025 revenue expected to exceed previous guidance of CHF65–70m and cash flow break-even targeted for mid-2026, Santhera is well-positioned to capitalise on AGAMREE’s momentum across expanding markets while maintaining disciplined cost control. The company maintains its FY28 revenue guidance of €150m and 2030 guidance of more than €150m in direct market sales alone.